Q-omics provides the consensus-scored EMP2P1 profile across patient tissues and cancer cell-line models. EMP2P1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, EMP2P1 is differentially expressed in 4, with the highest sampling consensus in KIRC. Additionally, EMP2P1 RNA expression shows 11,574 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRP, KIRC, and UVM as cancer lineages where EMP2P1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EMP2P1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EMP2P1 survival associations across molecular data types. EMP2P1 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EMP2P1 RNA expression–survival associations across cancer types. High EMP2P1 expression shows unfavorable associations in KIRP, UVM, THCA and ACC, but favorable associations in SKCM and HNSC. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for EMP2P1 RNA expression.
This table summarizes EMP2P1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for EMP2P1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EMP2P1 shows lower tumor expression in LUAD and THCA and higher tumor expression in KIRC and CHOL. The KIRC box plot shows higher EMP2P1 RNA expression in tumor versus normal tissue (log2 FC = +0.115, t-test p < 0.001).
This table shows molecular features associated with EMP2P1 in patient tissues and cancer cell lines. In patient samples, EMP2P1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
